Publications

1. Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna KH, Elliott M, Mangaonkar A, Matin A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Yates S, Sneider A, Dworkin E, Patel AA, Bazinet A, Senapati J, Bataller A, DiNardo C, Kadia T, Tefferi A. Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent. Am J Hematol. 2024 Dec 13 [Epub ahead of print]
   View PubMed
2. Xie Z, Fernandez J, Lasho T, Finke C, Amundson M, McCullough KB, LaPlant BR, Mangaonkar AA, Gangat N, Reichard KK, Elliott M, Witzig TE, Patnaik MM. High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations. Blood. 2024 Dec 5; 144 (23):2456-2461
   View PubMed
3. Mohammed Ismail W, Fernandez J, Binder M, Lasho TL, Kim M, Geyer S, Mazzone A, Finke CM, Mangaonkar AA, Lee JH, Wang L, Kim KH, Simon VA, Rakhshan Rohakthar F, Munankarmy A, Byeon SK, Schwager SM, Harington JJ, Snyder MR, Robertson KD, Pandey A, Wieben ED, Chia N, Gaspar-Maia A, Patnaik MM. Single cell multiomics reveal divergent effects of DNMT3A and TET2 mutant clonal hematopoiesis in inflammatory response. Blood Adv. 2024 Dec 4 Epub 2024 Dec 04
   View PubMed
4. Pennington KM, Simonetto D, Taner T, Mangaonkar AA. Pulmonary, Hepatic, and Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Telomere Biology Disorders. Curr Hematol Malig Rep. 2024 Dec; 19 (6):293-299 Epub 2024 Feb 05
   View PubMed
5. Modi P, Pennington K, Shah S, Mangaonkar A, Goswami U. Clinical Outcomes of Lung Transplant Recipients with Myelodysplastic Syndrome and Short Telomere Syndrome-Case Series. Transplant Proc. 2024 Dec; 56 (10):2237-2241 Epub 2024 Nov 30
   View PubMed
6. Tefferi A, Fathima S, Alsugair AKA, Aperna F, Natu A, Abdelmagid MG, Csizmar CM, Gurney M, Lasho TL, Finke CM, Mangaonkar AA, Al-Kali A, Pardanani A, Reichard KK, He R, Gangat N, Patnaik MM. PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis. Am J Hematol. 2024 Dec; 99 (12):2321-2327 Epub 2024 Sept 27
   View PubMed
7. Tremblay D, Csizmar C, DiNardo CD, Ball S, Rippel N, Hammond D, Kadia TM, Ravandi F, Chien K, Van Hyfte G, Mazumdar M, Saliba A, Mangaonkar A, Lasho T, Al-Kali A, Kremyanskaya M, Feld J, Silverman LR, Komrokji R, Mascarenhas J, Padron E, Garcia-Manero G, Sallman DA, Patnaik MM, Montalban-Bravo G. Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study. Leukemia. 2024 Nov 12 [Epub ahead of print]
   View PubMed
8. Jabban Y, Yacout M, Baranwal A, He R, Viswanatha D, Greipp P, Jevremovic D, Bessonen K, Foran J, Palmer J, Saliba AN, Hefazi-Torghabeh M, Begna K, Hogan WJ, Mangaonkar A, Patnaik M, Shah M, Alkhateeb H, Al-Kali A. Clinical outcomes of patients diagnosed with SETBP1 mutated myeloid neoplasms. Leuk Lymphoma. 2024 Nov 6; 1-10 Epub 2024 Nov 06
   View PubMed
9. Csizmar CM, Saliba AN, Greipp PT, Alkhateeb H, Begna KH, Foran JM, Gangat N, Hogan WJ, Hook CC, Litzow MR, Mangaonkar AA, Palmer JM, Pardanani A, Shah MV, Tefferi A, Torghabeh MH, Wolanskyj-Spinner AP, Patnaik MM, Kaufmann SH, Al-Kali A. FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(DEK::NUP214): the Mayo Clinic experience. Haematologica. 2024 Nov 1; 109 (11):3785-3789 Epub 2024 Nov 01
   View PubMed
10. Sullivan M, Mead-Harvey C, Sartori-Valinotti JC, Kalantari K, Kusne YN, Patnaik M, Mangaonkar AA, Go R, Montes D, Reichard K, Olteanu H, Bois M, Hines A, Warrington K, Koster MJ. Vasculitis associated with VEXAS syndrome. Rheumatology (Oxford). 2024 Oct 11 [Epub ahead of print]
    View PubMed
11. Baranwal A, Shah MV, Greipp P, Shi M, Reichard KK, Jevremovic D, Gangat N, Patnaik MM, Begna KH, Alkhateeb HB, Litzow MR, Hogan WJ, Tefferi A, Al-Kali A, Mangaonkar AA. Clinicopathologic correlates and prognostic impact of lymphoid aggregates in patients with myelodysplastic syndromes. Br J Haematol 2024 Oct; 205 (4):1627-1631 Epub 2024 July 31
    View PubMed
12. Katamesh B, Nanaa A, He R, Viswanatha D, Greipp PT, Bessonen K, Nguyen P, Jevremovic D, Yi CA, Foran J, Begna K, Gangat N, Mangaonkar A, Saliba AN, Patnaik MM, Hogan WJ, Litzow M, Tefferi A, Shah MV, Alkhateeb HB, Al-Kali A. Clonal heterogeneity in STAG2m myeloid neoplasms: the Mayo Clinic experience. Ann Hematol 2024 Oct; 103 (10):4333-4336 Epub 2024 Aug 28
    View PubMed
13. Csizmar CM, Gurney M, Kanagal-Shamanna R, Chien K, Hammond D, Lasho TL, Finke CM, Dean C, Natu A, Mangaonkar AA, Al-Kali A, Gangat N, Tefferi A, Alkhateeb H, Garcia-Manero G, Komrokji RS, Ali NA, Padron E, Montalban-Bravo G, Patnaik MM. ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia. Haematologica 2024 Oct 1; 109 (10):3419-3425 Epub 2024 Oct 01
    View PubMed
14. Kalantari K, Sullivan MM, Hernandez LPH, Bu L, Cornell LD, Nasr SH, Fervenza FC, Montes D, Mangaonkar AA, Go RS, Kusne YN, Patnaik MM, Lasho TL, Olteanu H, Reichard KK, Warrington KJ, Koster MJ. Acute kidney injury, an underrecognized feature of VEXAS syndrome. Rheumatology (Oxford). 2024 Aug 26 [Epub ahead of print]
    View PubMed
15. Baranwal A, Langer KJ, Kharfan-Dabaja MA, Ayala E, Foran J, Murthy H, Roy V, Iqbal M, Palmer J, Sproat LZ, Chhabra S, Khera N, Durani U, Hefazi M, Mangaonkar A, Shah MV, Litzow MR, Hogan WJ, Alkhateeb HB. Surrogates of Endothelial Injury Predict Survival After Post-transplant Cyclophosphamide. Transplant Cell Ther. 2024 Aug 16 [Epub ahead of print]
    View PubMed
16. Farrukh F, Abdelmagid M, Mangaonkar A, Patnaik M, Al-Kali A, Elliott MA, Begna KH, Hook CC, Hogan WJ, Pardanani A, Litzow MR, Ketterling RP, Gangat N, Arber DA, Orazi A, He R, Reichard K, Tefferi A. Prognostic impact of SF3B1 mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases. Haematologica. 2024 Aug 1; 109 (8):2525-2532 Epub 2024 Aug 01
    View PubMed
17. Steinauer N, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar AA, Saliba AN, Torghabeh M, Litzow MR, Hogan WJ, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Yi CA, Tefferi A, Gangat N. Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent. Haematologica 2024 Aug 1; 109 (8):2706-2710 Epub 2024 Aug 01
    View PubMed
18. Li M, Baranwal A, Gurney M, Shah SN, Al-Kali A, Alkhateeb H, Foran J, Arana Yi C, Ongie L, Chen D, Mangaonkar A, McCullough K, Tefferi A, Lasho T, Finke C, Patnaik MM, Shah MV. The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance. Blood Adv. 2024 Jun 25; 8 (12):3130-3139
    View PubMed
19. Olteanu H, Patnaik M, Koster MJ, Herrick JL, Chen D, He R, Viswanatha D, Warrington KJ, Go RS, Mangaonkar AA, Kourelis T, Hines A, Gibson SE, Peterson JF, Reichard KK. Comprehensive morphologic characterization of bone marrow biopsy findings in a large cohort of patients with VEXAS syndrome: A single-institution longitudinal study of 111 bone marrow samples from 52 patients. Am J Clin Pathol. 2024 Jun 3; 161 (6):609-624
    View PubMed
20. Baranwal A, Gurney M, Basmaci R, Katamesh B, He R, Viswanatha DS, Greipp P, Foran J, Badar T, Murthy H, Yi CA, Palmer J, Mangaonkar AA, Patnaik MM, Litzow MR, Hogan WJ, Begna K, Gangat N, Tefferi A, Al-Kali A, Shah MV, Alkhateeb HB. Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms. Haematologica. 2024 Jun 1; 109 (6):1779-1791 Epub 2024 June 01
    View PubMed
21. Kusne Y, Ghorbanzadeh A, Dulau-Florea A, Shalhoub R, Alcedo PE, Nghiem K, Ferrada MA, Hines A, Quinn KA, Panicker SR, Ombrello AK, Reichard K, Darden I, Goodspeed W, Durrani J, Wilson L, Olteanu H, Lasho T, Kastner DL, Warrington KJ, Mangaonkar A, Go RS, Braylan RC, Beck DB, Patnaik MM, Young NS, Calvo KR, Casanegra AI, Grayson PC, Koster MJ, Wu CO, Kanthi Y, Patel BA, Houghton DE, Groarke EM. Venous and arterial thrombosis in patients with VEXAS syndrome. Blood. 2024 May 23; 143 (21):2190-2200
    View PubMed
22. Baranwal A, Basmaci R, He R, Viswanatha D, Greipp P, Murthy HS, Foran J, Palmer J, Hogan WJ, Litzow MR, Hefazi M, Mangaonkar A, Shah MV, Al-Kali A, Alkhateeb HB. Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms. Blood Adv. 2024 Feb 13; 8 (3):562-570
    View PubMed
23. Koster MJ, Lasho TL, Olteanu H, Reichard KK, Mangaonkar A, Warrington KJ, Patnaik MM. VEXAS syndrome: Clinical, hematologic features and a practical approach to diagnosis and management. Am J Hematol. 2024 Feb; 99 (2):284-299 Epub 2023 Nov 11
    View PubMed
24. Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, Abdallah M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Tefferi A. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024 Feb; 99 (2):193-202 Epub 2023 Dec 10
    View PubMed
25. Xie Z, Lasho T, Khurana A, Ferrer A, Finke C, Mangaonkar AA, Ansell S, Fernandez J, Shah MV, Al-Kali A, Gangat N, Abeykoon J, Witzig TE, Patnaik MM. Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy. Haematologica. 2024 Feb 1; 109 (2):509-520 Epub 2024 Feb 01
    View PubMed
26. Begna KH, Abdallah NH, Janania-Martinez M, Mangaonkar AA, Rangan A, Herrick JL, Gangat N. Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant. Haematologica. 2024 Feb 1; 109 (2):689-692 Epub 2024 Feb 01
    View PubMed
27. Gangat N, McCullough K, Abdelmagid M, Karrar O, Powell M, Al-Kali A, Alkhateeb H, Begna K, Mangaonkar A, Saliba A, Torghabeh MH, Litzow M, Hogan W, Shah M, Patnaik M, Pardanani A, Badar T, Foran J, Palmer J, Sproat L, Yi CA, Tefferi A. Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia. Haematologica 2024 Jan 1; 109 (1):187-292 Epub 2024 Jan 01
    View PubMed
28. Ferrer A, Lasho T, Fernandez JA, Steinauer NP, Simon RA, Finke CM, Carmona EM, Wylam ME, Ongie LJ, Burnap BN, Arana Yi C, Sproat LZ, Foran J, Badar T, Mangaonkar AA, Patnaik MM. Patients with telomere biology disorders show context specific somatic mosaic states with high frequency of U2AF1 variants. Am J Hematol 2023 Dec; 98 (12):E357-E359 Epub 2023 Sept 04
    View PubMed
29. Badar T, Nanaa A, Foran JM, Viswanatha D, Al-Kali A, Lasho T, Finke C, Alkhateeb HB, He R, Gangat N, Shah M, Tefferi A, Mangaonkar AA, Litzow MR, Ongie LJ, Chlon T, Ferrer A, Patnaik MM. Clinical and molecular correlates of somatic and germline DDX41 variants in patients and families with myeloid neoplasms. Haematologica. 2023 Nov 1; 108 (11):3033-3043 Epub 2023 Nov 01
    View PubMed
30. Gangat N, Ilyas R, Johnson IM, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Tefferi A. Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy. Haematologica 2023 Nov 1; 108 (11):3170-3174 Epub 2023 Nov 01
    View PubMed
31. Badar T, Vanegas YAM, Nanaa A, Foran JM, Al-Kali A, Mangaonkar A, Murthy H, Alkhateeb HB, Viswanatha D, He R, Shah M, Yi CA, Litzow MR, Gangat N, Tefferi A, Patnaik MM. U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity. Blood Cancer J. 2023 Sep 21; 13 (1):149 Epub 2023 Sept 21
    View PubMed
32. Abdelmagid MG, Al-Kali A, Begna KH, Hogan WJ, Litzow MR, Fleti F, Mangaonkar AA, Patnaik MS, Elliott MA, Alkhateeb H, Shi M, Howard MT, Reichard KK, Ketterling RP, Shah M, Pardanani A, Gangat N, Tefferi A. Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival. Haematologica 2023 Sep 1; 108 (9):2542-2545 Epub 2023 Sept 01
    View PubMed
33. Gurney M, Mangaonkar AA, Lasho T, Finke C, Al-Kali A, Gangat N, Shah MV, Alkhateeb HB, Tefferi A, Sallman D, Xie Z, Viswanatha D, Reichard K, Al Ali N, Komrokji R, Padron E, Patnaik MM. Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML). Leukemia 2023 Aug; 37 (8):1753-1756 Epub 2023 July 08
    View PubMed
34. Gutierrez-Rodrigues F, Kusne Y, Fernandez J, Lasho T, Shalhoub R, Ma X, Alessi H, Finke C, Koster MJ, Mangaonkar A, Warrington KJ, Begna K, Xie Z, Ombrello AK, Viswanatha D, Ferrada M, Wilson L, Go R, Kourelis T, Reichard K, Olteanu H, Darden I, Hironaka D, Alemu L, Kajigaya S, Rosenzweig S, Calado RT, Groarke EM, Kastner DL, Calvo KR, Wu CO, Grayson PC, Young NS, Beck DB, Patel BA, Patnaik MM. Spectrum of clonal hematopoiesis in VEXAS syndrome. Blood. 2023 Jul 20; 142 (3):244-259
    View PubMed
35. Casal Moura M, Baqir M, Tandon YK, Samec MJ, Hines AS, Reichard KK, Mangaonkar AA, Go RS, Warrington KJ, Patnaik MM, Koster MJ, Ryu JH. Pulmonary manifestations in VEXAS syndrome. Respir Med. 2023 Jul; 213:107245. Epub 2023 Apr 14.
    View PubMed
36. Gurney M, Chekkaf I, Baranwal A, Basmaci R, Katamesh B, Greipp P, Foran JM, Badar T, Mangaonkar AA, Begna KH, Gangat N, Patnaik MM, Litzow MR, Shah MV, Viswanatha DS, He R, Alkhateeb HB, Al-Kali A. The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms. Br J Haematol. 2023 Jul; 202 (2):279-283 Epub 2023 May 05
    View PubMed
37. Hines AS, Mohandesi NA, Lehman JS, Koster MJ, Cantwell HM, Alavi A, Warrington KJ, Mangaonkar AA, Go RS, Patnaik MM, Sartori-Valinotti JC. Cutaneous involvement in VEXAS syndrome: clinical and histopathologic findings. Int J Dermatol. 2023 Jul; 62(7):938-945. Epub 2023 Mar 08.
    View PubMed
38. Baranwal A, Chhetri R, Yeung D, Clark M, Shah S, Litzow MR, Hogan WJ, Mangaonkar A, Alkhateeb HB, Singhal D, Cibich A, Bardy P, Kok CH, Hiwase DK, Shah MV. Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study. Bone Marrow Transplant. 2023 Jul; 58 (7):769-776 Epub 2023 Apr 03
    View PubMed
39. Gangat N, Kuykendall A, Al Ali N, Goel S, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Komrokji R, Tefferi A. Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival. Blood Adv. 2023 Jun 27; 7 (12):2694-2698
    View PubMed
40. Lasho T, Finke C, Timm M, Tefferi A, Mangaonkar A, Olteanu H, Reichard K, Ketterling R, Gangat N, Xie Z, Fernandez J, Chia N, Gaspar-Maia A, Binder M, Patnaik MM. Single cell proteogenomic analysis of aberrant monocytosis in TET2 mutant premalignant and malignant hematopoiesis. Leukemia 2023 Jun; 37 (6):1384-1387 Epub 2023 Mar 25
    View PubMed
41. Mangaonkar AA, Patnaik MM. Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2023 update on clinical associations and management recommendations. Am J Hematol. 2023 Jun; 98 (6):951-964 Epub 2023 Mar 30
    View PubMed
42. Acosta-Medina AA, Baranwal A, Johnson IM, Kharfan-Dabaja MA, Murthy H, Palmer JM, Sproat L, Mangaonkar A, Shah MV, Hogan WJ, Litzow MR, Tefferi A, Alkhateeb HB. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation. Transplant Cell Ther. 2023 Jun; 29 (6):360.e1-360.e8 Epub 2023 Feb 09
    View PubMed
43. Matin A, Smith BH, Mangaonkar A, Duffy DJ, Wolf R, Alkhateeb H, Shah MV, Hogan WJ, Litzow MR. Pericardial Effusion as a Purported Manifestation of Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2023 May; 29 (5):324.e1-324.e6 Epub 2023 Jan 20
    View PubMed
44. Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Bessonen K, Gangat N, Begna K, Mangaonkar A, Patnaik M, Hogan WJ, Tefferi A, Litzow M, Shah MV, Yi CA, Foran J, Badar T, Alkhateeb HB, Al-Kali A. Clinical and prognostic impact of STAG2 mutations in myeloid neoplasms: the Mayo Clinic experience. Blood Adv. 2023 Apr 25; 7 (8):1351-1355
    View PubMed
45. Al-Kali A, Nanaa A, Viswanatha D, He R, Nguyen P, Jevremovic D, Foran JM, Yi CA, Greipp PT, Gangat N, Patnaik M, Tefferi A, Litzow MR, Mangaonkar AA, Shah MV, Badar T, Alkhateeb HB. Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome. Blood Cancer J 2023 Apr 10; 13 (1):49
    View PubMed
46. Hiwase D, Hahn C, Tran ENH, Chhetri R, Baranwal A, Al-Kali A, Sharplin K, Ladon D, Hollins R, Greipp P, Kutyna M, Alkhateeb H, Badar T, Wang P, Ross DM, Singhal D, Shanmuganathan N, Bardy P, Beligaswatte A, Yeung D, Litzow MR, Mangaonkar A, Giri P, Lee C, Yong A, Horvath N, Singhal N, Gowda R, Hogan W, Gangat N, Patnaik M, Begna K, Tiong IS, Wei A, Kumar S, Brown A, Scott H, Thomas D, Kok CH, Tefferi A, Shah MV. TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. Blood. 2023 Mar 2; 141 (9):1087-1091
    View PubMed
47. Singhal S, Saadeh SS, Durani U, Kansagra A, Alkhateeb HB, Shah MV, Mangaonkar A, Kenderian S, Hashmi S, Patnaik MV, Litzow MR, Hogan WJ. Allogeneic Hematopoietic Stem Cell Transplantation in the Outpatient Setting: The Mayo Clinic Experience. Transplant Cell Ther. 2023 Mar; 29 (3):183.e1-183.e6 Epub 2022 Dec 28
    View PubMed
48. Pritzl SL, Gurney M, Badar T, Ferrer A, Lasho T, Finke C, Mangaonkar A, McCullough K, Gangat N, Fernandez J, Al-Kali A, Viswanatha D, He R, Foran J, Patnaik MM. Clinical and molecular spectrum and prognostic outcomes of U2AF1 mutant clonal hematopoiesis- a prospective mayo clinic cohort study. Leuk Res. 2023 Feb; 125:107007 Epub 2022 Dec 28
    View PubMed
49. Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Foran J, Begna K, Gangat N, Patnaik M, Tefferi A, Litzow M, Mangaonkar A, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Co-mutational pattern of somatic GATA2-mutated myeloid neoplasms. Ann Hematol 2023 Jan; 102 (1):211-212 Epub 2022 Nov 04
    View PubMed
50. Tefferi A, Singh A, Gangat N, Al-Kali A, Alkhateeb H, Shah M, Patnaik MS, Elliott MA, Hogan WJ, Litzow MR, Wolanskyj-Spinner A, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Begna KH, Ketterling RP. Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival. Haematologica 2023 Jan 1; 108 (1):245-249 Epub 2023 Jan 01
    View PubMed
51. Katamesh B, Nanaa A, He R, Viswanatha D, Nguyen P, Greipp P, Foran J, Begna K, Gangat N, Patnaik M, Tefferi A, Litzow M, Mangaonkar A, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Autoimmune manifestations in STAG2-mutated myeloid neoplasms. Ann Hematol 2022 Dec; 101 (12):2785-2787 Epub 2022 Oct 03
    View PubMed
52. Gangat N, Johnson I, McCullough K, Farrukh F, Al-Kali A, Alkhateeb H, Begna K, Mangaonkar A, Litzow M, Hogan W, Shah M, Patnaik M, Pardanani A, Tefferi A. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naive acute myeloid leukemia. Haematologica. 2022 Oct 1; 107 (10):2501-2505 Epub 2022 Oct 01
    View PubMed
53. Tefferi A, Gangat N, Shah M, Alkhateeb H, Patnaik MS, Al-Kali A, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Ketterling RP, Begna KH. Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience. Haematologica. 2022 Oct 1; 107 (10):2474-2479 Epub 2022 Oct 01
    View PubMed
54. Nanaa A, He R, Viswanatha D, Nguyen P, Jevremovic D, Foran JM, Yi CA, Greipp PT, Gangat N, Patnaik M, Tefferi A, Litzow MR, Mangaonkar AA, Shah MV, Badar T, Alkhateeb HB, Al-Kali A. Comparison between GATA2 and DDX41-mutated myeloid neoplasms. Leuk Res 2022 Oct; 121:106931 Epub 2022 Aug 23
    View PubMed
55. Tefferi A, Gangat N, Al-Kali A, Alkhateeb H, Shah M, Patnaik MS, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Ketterling RP, DiNardo CD, Kadia TM, Ravandi F, Sasaki K, Begna KH. A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. Am J Hematol. 2022 Sep; 97 (9):1127-1134 Epub 2022 June 30
    View PubMed
56. Mangaonkar AA, Patnaik MM. Role of the bone marrow immune microenvironment in chronic myelomonocytic leukemia pathogenesis: novel mechanisms and insights into clonal propagation. Leuk Lymphoma. 2022 Aug; 63 (8):1792-1800 Epub 2022 Apr 04
    View PubMed
57. Kutzke JL, Merten JA, Pawlenty AG, Barreto EF, Bartoo GT, Mara KC, Litzow MR, Hogan WJ, Shah MV, Mangaonkar AA, Leung N, Alkhateeb HB. Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning. Blood Adv. 2022 Jul 12; 6 (13):3844-3849
    View PubMed
58. Shah MV, Mangaonkar AA, Begna KH, Alkhateeb HB, Greipp P, Nanaa A, Elliott MA, Hogan WJ, Litzow MR, McCullough K, Tefferi A, Gangat N, Patnaik MM, Al-Kali A, He R, Chen D. Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms. Blood Cancer J. 2022 Jul 8; 12 (7):106 Epub 2022 July 08
    View PubMed
59. Farrukh F, Chetram D, Al-Kali A, Foran J, Patnaik M, Badar T, Begna K, Hook C, Hogan W, McCullough KB, Mangaonkar A, He R, Gangat N, Tefferi A. Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts. Am J Hematol 2022 Jun 1; 97 (6):E210-E214 Epub 2022 Mar 29
    View PubMed
60. Walsh C, Hunter A, Lasho T, Finke C, Ketterling R, Komrokji R, Tefferi A, Mangaonkar A, Howard M, Gangat N, Al-Kali A, Ali NA, Padron E, Patnaik MM. Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia. Leukemia. 2022 Jun; 36 (6):1693-1696 Epub 2022 Mar 29
    View PubMed
61. Ferrer A, Mangaonkar AA, Patnaik MM. Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders. Curr Hematol Malig Rep. 2022 Jun; 17 (3):61-68 Epub 2022 May 07
    View PubMed
62. Mangaonkar AA, Lasho TL, Finke C, Ketterling RP, Reichard KK, McCullough K, Gangat N, Al-Kali A, Begna KH, Hogan WH, Litzow MR, Alkhateeb H, Shah M, Pardanani A, Tefferi A, Al Ali NH, Talati C, Sallman D, Padron E, Komrokji R, Patnaik MM. SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity. Haematologica. 2022 May 1; 107 (5):1189-1192 Epub 2022 May 01
    View PubMed
63. Begna KH, Xu X, Gangat N, Alkhateeb H, Patnaik MM, Al-Kali A, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Wolanskyj-Spinner AP, Mangaonkar A, He R, Pardanani A, Shah M, Ketterling RP, Tefferi A. Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3". Blood Cancer J 2022 Apr 7; 12 (4):55 Epub 2022 Apr 07
    View PubMed
64. Binder M, Carr RM, Lasho TL, Finke CM, Mangaonkar AA, Pin CL, Berger KR, Mazzone A, Potluri S, Ordog T, Robertson KD, Marks DL, Fernandez-Zapico ME, Gaspar-Maia A, Patnaik MM. Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia. Nat Commun. 2022 Mar 17; 13 (1):1434
    View PubMed
65. You X, Liu F, Binder M, Vedder A, Lasho T, Wen Z, Gao X, Flietner E, Rajagopalan A, Zhou Y, Finke C, Mangaonkar A, Liao R, Kong G, Ranheim EA, Droin N, Hunter AM, Nikolaev S, Balasis M, Abdel-Wahab O, Levine RL, Will B, Nadiminti KVG, Yang D, Geissler K, Solary E, Xu W, Padron E, Patnaik MM, Zhang J. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation. Blood. 2022 Feb 17; 139 (7):1066-1079
    View PubMed
66. Rattan P, Penrice DD, Ahn JC, Ferrer A, Patnaik M, Shah VH, Kamath PS, Mangaonkar AA, Simonetto DA. Inverse Association of Telomere Length With Liver Disease and Mortality in the US Population. Hepatol Commun. 2022 Feb; 6 (2):399-410 Epub 2021 Aug 28
    View PubMed
67. Mangaonkar AA, Lasho TL, Ketterling RP, Reichard KK, Gangat N, Al-Kali A, Begna KH, Pardanani A, Al Ali NH, Talati C, Sallman D, Padron E, Patnaik MM, Tefferi A, Komrokji R. Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. Blood Cancer J. 2022 Feb 1; 12 (2):26 Epub 2022 Feb 01
    View PubMed
68. Alkhateeb HB, Nanaa A, Viswanatha D, Foran JM, Badar T, Sproat L, He R, Nguyen P, Jevremovic D, Salama ME, Greipp P, Gangat N, Tefferi A, Litzow MR, Mangaonkar AA, Shah MV, Patnaik M, Al-Kali A. Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms. Blood Adv. 2022 Jan 25; 6 (2):528-532
    View PubMed
69. Martin ES, Ferrer A, Mangaonkar AA, Khan SP, Kohorst MA, Joshi AY, Hogan WJ, Olteanu H, Moyer AM, Al-Kali A, Tefferi A, Chen D, Wudhikarn K, Go R, Viswanatha D, He R, Ketterling R, Nguyen PL, Oliveira JL, Gangat N, Lasho T, Patnaik MM. Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. Am J Hematol. 2021 Nov 1; 96 (11):1450-1460 Epub 2021 Aug 27
    View PubMed
70. Mangaonkar AA, Swoboda DM, Lasho TL, Finke C, Ketterling RP, Reichard KK, Padron E, Talati C, Patnaik MM. Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted. Leukemia. 2021 Nov; 35 (11):3329-3333 Epub 2021 Apr 30
    View PubMed
71. Mangaonkar AA, Ferrer A, Vairo FPE, Hammel CW, Prochnow C, Gangat N, Hogan WJ, Litzow MR, Peters SG, Scott JP, Utz JP, Baqir M, Carmona-Porquera EM, Kalra S, Sekiguchi H, Khan SP, Simonetto DA, Klee EW, Kamath PS, Roden AC, Joshi AY, Kennedy CC, Wylam ME, Patnaik MM. Clinical and molecular correlates from a predominantly adult cohort of patients with short telomere lengths. Blood Cancer J 2021 Oct 22; 11 (10):170
    View PubMed
72. Koster MJ, Kourelis T, Reichard KK, Kermani TA, Beck DB, Cardona DO, Samec MJ, Mangaonkar AA, Begna KH, Hook CC, Oliveira JL, Nasr SH, Tiong BK, Patnaik MM, Burke MM, Michet CJ Jr, Warrington KJ. Clinical Heterogeneity of the VEXAS Syndrome: A Case Series. Mayo Clin Proc. 2021 Oct; 96 (10):2653-2659 Epub 2021 Sept 03
    View PubMed
73. St Martin EC, Ferrer A, Wudhikarn K, Mangaonkar A, Hogan W, Tefferi A, Gangat N, Lasho T, Altman JK, Godley LA, Patnaik MM. Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes. Am J Hematol 2021 Sep 1; 96 (9):E327-E330 Epub 2021 June 04
    View PubMed
74. Cecchini MJ, Tarmey T, Ferreira A, Mangaonkar AA, Ferrer A, Patnaik MM, Wylam ME, Jenkins SM, Spears GM, Yi ES, Hartman TE, Scott JP, Roden AC. Pathology, Radiology, and Genetics of Interstitial Lung Disease in Patients With Shortened Telomeres. Am J Surg Pathol. 2021 Jul 1; 45 (7):871-884
    View PubMed
75. Mangaonkar AA, Tande AJ, Bekele DI. Differential Diagnosis and Workup of Monocytosis: A Systematic Approach to a Common Hematologic Finding. Curr Hematol Malig Rep. 2021 Jun; 16 (3):267-275 Epub 2021 Apr 20
    View PubMed
76. Carr RM, Vorobyev D, Lasho T, Marks DL, Tolosa EJ, Vedder A, Almada LL, Yurcheko A, Padioleau I, Alver B, Coltro G, Binder M, Safgren SL, Horn I, You X, Solary E, Balasis ME, Berger K, Hiebert J, Witzig T, Buradkar A, Graf T, Valent P, Mangaonkar AA, Robertson KD, Howard MT, Kaufmann SH, Pin C, Fernandez-Zapico ME, Geissler K, Droin N, Padron E, Zhang J, Nikolaev S, Patnaik MM. RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nat Commun. 2021 May 18; 12 (1):2901
    View PubMed
77. Li M, Binder M, Lasho T, Ferrer A, Gangat N, Al-Kali A, Mangaonkar A, Elliott M, Litzow M, Hogan W, Pardanani A, Wolanskyj-Spinner A, Howard M, King RL, Shah M, Alkhateeb H, Begna K, Tefferi A, Finke C, Oliveira J, Ketterling R, Olteanu H, Patnaik MM. Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. Blood Adv. 2021 Apr 27; 5 (8):2272-2278
    View PubMed
78. Schultz-Rogers L, Lach FP, Rickman KA, Ferrer A, Mangaonkar AA, Schwab TL, Schmitz CT, Clark KJ, Dsouza NR, Zimmermann MT, Litzow M, Jacobi N, Klee EW, Smogorzewska A, Patnaik MM. A homozygous missense variant in UBE2T is associated with a mild Fanconi anemia phenotype. Haematologica 2021 Apr 1; 106 (4):1188-1192 Epub 2021 Apr 01
    View PubMed
79. Bezerra ED, Lasho TL, Finke CM, Saliba AN, Elliott MA, Pardanani AD, Gangat N, Mangaonkar AA, Ketterling RP, Tefferi A, Solary E, Patnaik MM. CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. Blood Cancer J 2021 Mar 11; 11 (3):54
    View PubMed
80. Buradkar A, Bezerra E, Coltro G, Lasho TL, Finke CM, Gangat N, Carr RM, Binder M, Mangaonkar AA, Ketterling R, Khan S, Rodriguez V, Tefferi A, Patnaik MM. Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. Leukemia. 2021 Feb; 35 (2):644-649 Epub 2020 June 08
    View PubMed
81. Wudhikarn K, Loghavi S, Mangaonkar AA, Al-Kali A, Binder M, Carr R, Reichard K, Finke C, Howard M, Gangat N, Tefferi A, Komrokji R, Ali N, Lasho T, Ketterling R, Padron E, Patnaik MM. SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. Blood Adv 2020 Nov 24; 4 (22):5716-5721
    View PubMed
82. Ferrer A, Mangaonkar AA, Stroik S, Zimmermann MT, Sigafoos AN, Kamath PS, Simonetto DA, Wylam ME, Carmona EM, Lazaridis KN, Peters S, Stewart K, Klee EW, Hendrickson EA, Patnaik MM. Functional validation of TERT and TERC variants of uncertain significance in patients with short telomere syndromes. Blood Cancer J 2020 Nov 17; 10 (11):120
    View PubMed
83. Mangaonkar AA, Reichard KK, Binder M, Coltro G, Lasho TL, Carr RM, Chiu A, Negron V, Hefazi M, Anagnostou T, Timm MM, Hiebert JW, Villasboas JC, Gonsalves WI, Gangat N, Shah M, Alkhateeb HB, Al-Kali A, Elliott MA, Begna KH, Wolanskyj-Spinner AP, Litzow MR, Hogan WJ, Ansell SM, Pardanani A, Tefferi A, Patnaik MM. Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. Blood Adv. 2020 Nov 10; 4(21):5425-5430.
    View PubMed
84. Saliba AN, Ferrer A, Gangat N, Pruthi RK, Tefferi A, Higgins A, Bezerra ED, Buglioni A, Salama ME, Klee EW, Pinto E Vairo F, Mangaonkar A, Majerus J, Chen D, Patnaik MM. Aetiology and outcomes of secondary myelofibrosis occurring in the context of inherited platelet disorders: A single institutional study of four patients. Br J Haematol 2020 Sep; 190 (5):e316-e320 Epub 2020 June 22
    View PubMed
85. DiFilippo EC, Coltro G, Carr RM, Mangaonkar AA, Binder M, Khan SP, Rodriguez V, Gangat N, Wolanskyj A, Pruthi RK, Chen D, He R, Viswanatha DS, Lasho T, Finke C, Tefferi A, Pardanani A, Patnaik MM. Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS/MPN overlap neoplasms. Leukemia 2020 Sep; 34 (9):2519-2524 Epub 2020 Feb 14
    View PubMed
86. Patnaik MM, Sallman DA, Mangaonkar AA, Heuer R, Hirvela J, Zblewski D, Al-Kali A, Binder M, Balasis ME, Newman H, Letson C, Kruer TL, Gangat N, Komrokji RS, Tefferi A, Lo A, Shih T, Durrant C, List AF, Padron E. Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood. 2020 Aug 13; 136 (7):909-913
    View PubMed
87. Mangaonkar AA, Patnaik MM. Hereditary Predisposition to Hematopoietic Neoplasms: When Bloodline Matters for Blood Cancers. Mayo Clin Proc. 2020 Jul; 95 (7):1482-1498 Epub 2020 June 19
    View PubMed
88. Mangaonkar AA, Thawer F, Son J, Ajebo G, Xu H, Barrett NJ, Wells LG, Bowman L, Clair B, Patel N, Bora P, Jung G, Nemeth E, Kutlar A. Regulation of iron homeostasis through the erythroferrone-hepcidin axis in sickle cell disease. Br J Haematol. 2020 Jun; 189 (6):1204-1209 Epub 2020 Feb 06
    View PubMed
89. Coltro G, Mangaonkar AA, Lasho TL, Finke CM, Pophali P, Carr R, Gangat N, Binder M, Pardanani A, Fernandez-Zapico M, Robertson KD, Bosi A, Droin N, Vannucchi AM, Tefferi A, Hunter A, Padron E, Solary E, Patnaik MM. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients. Leukemia. 2020 May; 34 (5):1407-1421 Epub 2019 Dec 13
    View PubMed
90. Mangaonkar AA, Patnaik MM. Treatment of Acquired Sideroblastic Anemias. Hematol Oncol Clin North Am. 2020 Apr; 34 (2):401-420 Epub 2020 Jan 21
    View PubMed
91. Mangaonkar AA, Swoboda DM, Coltro G, Lasho TL, Novotny PJ, Pophali P, Carr RM, Binder M, Finke CM, Gangat N, Al-Kali A, Begna KH, Reichard KK, Ketterling RP, Al Ali NH, Vafaii P, Zhang L, Padron E, Talati C, Patnaik MM. Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. Leukemia 2020 Feb; 34 (2):656-661 Epub 2019 Sept 11
    View PubMed
92. Mangaonkar AA, Ferrer A, Pinto E Vairo F, Cousin MA, Kuisle RJ, Gangat N, Hogan WJ, Litzow MR, McAllister TM, Klee EW, Lazaridis KN, Stewart AK, Patnaik MM. Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias. Mayo Clin Proc. 2019 Sep; 94 (9):1753-1768 Epub 2019 June 27
    View PubMed
93. Pophali PA, Timm MM, Mangaonkar AA, Shi M, Shi M, Reichard K, Tefferi A, Pavelko K, Villasboas JC, Jevremovic D, Patnaik MM. Practical limitations of monocyte subset repartitioning by multiparametric flow cytometry in chronic myelomonocytic leukemia. Blood Cancer J 2019 Aug 16; 9 (9):65
    View PubMed
94. Coston T, Pophali P, Vallapureddy R, Lasho TL, Finke CM, Ketterling RP, Carr R, Binder M, Mangaonkar AA, Gangat N, Al-Kali A, Litzow M, Zblewski D, Pardanani A, Tefferi A, Patnaik MM. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. Am J Hematol. 2019 Jul; 94 (7):767-779 Epub 2019 May 03
    View PubMed
95. Patnaik MM, Pophali PA, Lasho TL, Finke CM, Horna P, Ketterling RP, Gangat N, Mangaonkar AA, Pardanani A, Tefferi A. Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation. Haematologica 2019 Jun; 104 (6):e236-e239 Epub 2019 Jan 03
    View PubMed
96. Peterson JF, Baughn LB, Ketterling RP, Pitel BA, Smoley SA, Vasmatzis G, Smadbeck JB, Greipp PT, Mangaonkar AA, Thompson CA, Parikh SA, Chen D, Viswanatha DS. Characterization of a cryptic IGH/CCND1 rearrangement in a case of mantle cell lymphoma with negative CCND1 FISH studies. Blood Adv. 2019 Apr 23; 3 (8):1298-1302
    View PubMed
97. Mangaonkar AA, Patnaik MM. Advances in chronic myelomonocytic leukemia and future prospects: Lessons learned from precision genomics. Adv Cell Gene Ther. 2019 Apr; 2 (2) Epub 2019 Jan 16
    View PubMed
98. Mangaonkar AA, Patnaik MM, Oliver GR, Rao KW, Kaiser-Rogers K, Davila JI, Fadra N, Wehrs RN, Elliott MA, Greipp PT, Halling KC, Van Dyke DL. Multiple isodicentric Y chromosomes in myeloid malignancies: a unique cytogenetic entity and potential therapeutic target. Leuk Lymphoma 2019 Mar; 60 (3):821-824 Epub 2018 Aug 30
    View PubMed
99. Higgins A, Mangaonkar AA, Hefazi M, Viswanatha D, Horna P, Foran J, Gangat N. Non-internal tandem duplication (ITD), non-tyrosine kinase domain (TKD) FLT3 mutations in myeloid malignancies: A brief report of 10 patients. Leuk Res 2018 Sep; 72:1-4 Epub 2018 July 21
    View PubMed
100. Mangaonkar AA, Gangat N, Al-Kali A, Elliott MA, Begna KH, Hanson CA, Ketterling RP, Wolanskyj-Spinner AP, Hogan WJ, Litzow MR, Patnaik MM. Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. Leuk Res. 2018 Aug; 71:60-62 Epub 2018 July 11
     View PubMed
101. Mangaonkar AA, Ferrer A, Pinto E Vairo F, Cousin MA, Kuisle RJ, Klee EW, Kennedy CC, Peters SG, Scott JP, Utz JP, Baqir M, Sekiguchi H, Khan SP, Rodriguez V, Simonetto DA, Kamath PS, Abraham RS, Wylam ME, Patnaik MM. Clinical Correlates and Treatment Outcomes for Patients With Short Telomere Syndromes. Mayo Clin Proc. 2018 Jul; 93 (7):834-839
     View PubMed
102. Mangaonkar AA, Patnaik MM. Short Telomere Syndromes in Clinical Practice: Bridging Bench and Bedside. Mayo Clin Proc. 2018 Jul; 93 (7):904-916 Epub 2018 May 24
     View PubMed
103. Mangaonkar AA, Hoversten KP, Gangat N. Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia. Expert Rev Hematol. 2018 Mar; 11 (3):247-252 Epub 2018 Jan 20
     View PubMed
104. Mangaonkar A, Mondal AK, Fulzule S, Pundkar C, Park EJ, Jillella A, Kota V, Xu H, Savage NM, Shi H, Munn D, Kolhe R. A novel immunohistochemical score to predict early mortality in acute myeloid leukemia patients based on indoleamine 2,3 dioxygenase expression. Sci Rep. 2017 Oct 16; 7 (1):12892
     View PubMed
105. Haddox CL, Mangaonkar AA, Chen D, Shi M, He R, Oliveira JL, Litzow MR, Al-Kali A, Hogan WJ, Elliott MA. Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis. Blood Cancer J 2017 Sep 15; 7 (9):e607 Epub 2017 Sept 15
     View PubMed
106. Mangaonkar AA, Patnaik MM. Patterns of Care and Survival for Elderly Acute Myeloid Leukemia-Challenges and Opportunities. Curr Hematol Malig Rep. 2017 Aug; 12 (4):290-299
     View PubMed
107. Mangaonkar A, Khateeb HA, Duma N, St Louis EK, McKeon A, Patnaik M, Hogan W, Litzow M, Kourelis T. Immune-Mediated Autonomic Neuropathies following Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia. Case Rep Hematol. 2017; 2017:6803804 Epub 2017 Aug 27
     View PubMed
108. Mansour J, Mangaonkar A, Kota V. Recurrent Parotid Carcinosarcoma in an Asymptomatic Patient. J Investig Med High Impact Case Rep. 2016 Oct-Dec; 4 (4):2324709616676590 Epub 2016 Nov 04
     View PubMed
109. Mangaonkar A, Xu H, Mohsin J, Mansour J, Chintalapally R, Keen R, Mondal AK, DeRemer D, Clemmons AB, Clark SM, Shah A, Jillela A, Kolhe R, Kota V. Prognostic value of complete remission with superior platelet counts in acute myeloid leukemia. J Community Support Oncol. 2016 Feb; 14 (2):66-71
     View PubMed
110. Shah A, Mangaonkar A. Idelalisib: A Novel PI3Kdelta Inhibitor for Chronic Lymphocytic Leukemia. Ann Pharmacother. 2015 Oct; 49 (10):1162-70 Epub 2015 July 16
     View PubMed
111. Mangaonkar A, Mansour J, Keen R, Kukkadapu T, Chintalapally R, Kota V. Pneumatosis Intestinalis in a Patient with Acute Promyelocytic Leukemia. Case Rep Hematol. 2015; 2015:576042.
     View PubMed
112. Yu M, Mangaonkar A, Lovelace C, Ibe M. Pyogenic hepatic abscess presenting years after a choledochojejunostomy: a rare clinical occurrence. BMJ Case Rep. 2014 Jun 09; 2014:
     View PubMed
113. Mangaonkar AA, Gupta HR, Bera BM, Barmare S. Bone marrow fibrosis and metastatic prostate adenocarcinoma. BMJ Case Rep. 2012 Dec 12; 2012:
     View PubMed